Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
The country’s strength lies not just in technology availability but in adoption behaviour
Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The company reported free cash flow of Rs. 2,590 Mn for FY26
Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
Subscribe To Our Newsletter & Stay Updated
